1 domain / 2 areas / 1 specialization
RTW Venture Fund
Data updated
RTW Venture Fund is a life sciences investment vehicle associated with RTW Investments, LP, which describes itself as a New York-based, global, full life-cycle investment firm focused on biopharmaceutical and medical technology innovation. Public RTW materials describe the platform as investing across the lifecycle, including venture, crossover, and public company investments.
In the psychedelic ecosystem, RTW Venture Fund appears relevant mainly through adjacent neuropsychiatric and drug-development investing rather than a stated psychedelic-only mandate. RTW has also backed Amani Therapeutics, a company developing a therapy for serious neuropsychiatric disorders, which suggests interest in central nervous system programs that may overlap with psychedelic-adjacent clinical and translational work.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
RTW Venture Fund is best described as a life sciences investor with a long-term, full-lifecycle approach that spans early venture, private financings, and public-market exposure. Its public materials emphasize drug development expertise and investments in biopharma and medtech across modalities, making it a plausible fit for psychedelic-adjacent companies focused on neuropsychiatric medicine, clinical development, or novel therapeutics. Publicly available RTW materials do not indicate a dedicated psychedelic strategy, so its relevance to the sector should be treated as adjacent rather than specialized.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Quick Facts
- HQ
- New York, NY, United States
- Website
- Visit